drug

risankizumab-rzaa

1 story · latest Jul 31, 2026

Status: FDA approved Apr 2019 · BLA761105, BLA761262
Brand: Skyrizi
Codes: ABBV-066, BI 655066
Trials: 10 registered trials in coverage

Relationships

Developed by AbbVie

Developed by MoonLake Immunotherapeutics AG

Also known as

risankizumab, risankizumab on-body injector

Timeline

AbbVie to acquire Apogee Therapeutics, updates 2026 EPS guidance amid Q2 results

Jul 31Quarterly updateAbbVie

Biotech intelligence from primary sources. Every story is an original summary of a public record, linked to its source. Not investment advice.

Terms Privacy hello@readthrough.news

readthrough is a product of JAMN Ventures, LLC.